Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Laekna Inc
2105Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China. Address: 3-2-467, 5 Xingbin Road, Yuyao, China
Analytics
Zielpreis von Wall Street
–KGV
17.16Dividendenrendite
–Schlüsselzahlen 2105
- Gewinnspanne
- Gesamtumsatz
- Bruttogewinn
Dividenden-Analyse 2105
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende 2105
- Auszahlungsquote
- Dividends
- Dividendenrendite
Bewertung der Aktie 2105
- KUV
- KGV
- Kurs-Buchwert-Verhältnis
Finanzen 2105
Verfolgen Sie wichtige Kennzahlen für jede Aktie problemlos an einem Ort
Premium bekommenErgebnisse | 2019 | Dynamik |